CoChat

NONINFECTIOUS VITRITIS AFTER INTRAVITREAL INJECTION OF ANTI-VEGF AGENTS: Variations in Rates and Presentation by Medication

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

In Brief Purpose: The purpose of this study was to describe and compare the rates and characteristics of noninfectious vitritis after intravitreal injection of bevacizumab (Avastin, Genentech, South San Francisco, CA), ranibizumab (Lucentis, Genentech), and aflibercept (Eylea, Regeneron, Tarrytown, NY). Methods: A retrospective case series evaluated intravitreal injections from 2006 to 2013. Cases of inflammatory response were separated into culture-positive endophthalmitis, noninfectious vitritis (not treated with intravitreal antibiotics), and indeterminate. Noninfectious cases were analyzed for rate, presentation, and clinical course. Results: A total of 66,356 bevacizumab, 26,161 ranibizumab, and 8071 aflibercept injections were screened. The rates of noninfectious vitritis were 0.10% (67 cases) for bevacizumab, 0.02% (6 cases) for ranibizumab, and 0.16% (13 cases) for aflibercept. The differences were statistically significant based on Chi-square analysis (P < 0.001). Mean differences in visual decline were not significant by Kruskal–Wallis analysis (P = 0.12), but the percentage of patients with any visual decline did vary by medication according to Fisher exact test (P < 0.05). The percentage of patients with complaints of pain, blurred vision, and subjective floaters was not significantly different by medication based on Fisher exact testing (P = 0.2, P = 0.18, P = 0.16, respectively). Bevacizumab and aflibercept cases tended to present in separate chronological clusters. Conclusion: The results suggest a difference in rates of noninfectious vitritis for antivascular endothelial growth factor medications. Many cases tended to cluster instead of occurring at a consistent rate each year. Noninfectious inflammatory responses are uncommon occurrences after intravitreal injection of antivascular endothelial growth factor. This study describes differences in rates and clinical characteristics of vitritis after bevacizumab, ranibizumab, and aflibercept injections. Records of intravitreal injections from 2006 to 2013 were reviewed.

Overview

Integrity signals

Registry

Crossref · 10.1097/iae.0000000000000801

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 16 references

Cited by

See all 69

Metadata

Authors
Williams, P. D., Chong, D., Fuller, T., & Callanan, D.
Affiliations
Texas Retina Associates (United States) (US)
Venue
Retina
Published
2016-05
Volume
36
Issue
5
Pages
909-913
ISSN
0275-004X (ISSN-L)
OpenAlex
W2331904769
Cited by
69
References
16
Citations by year
2026: 5 · 2025: 12 · 2024: 5 · 2023: 4 · 2022: 8 · 2021: 13 · 2020: 6 · 2019: 8 · 2018: 4 · 2017: 4
FWCI
2.56
Type
journal article
Language
en
Open access
closed
Locations
  • Retina (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
  • Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
Keywords
intravitreal injection, VEGF inhibitors, bevacizumab, ranibizumab, aflibercept, endophthalmitis, visual deterioration, adverse events
MeSH terms
Bevacizumab, Ranibizumab, Aged, Aged, 80 and over, Eye Diseases, Female, Humans, Macular Degeneration, Male, Recombinant Fusion Proteins, Retinal Vein Occlusion, Retrospective Studies, Vitreous Body, Angiogenesis Inhibitors, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Intravitreal Injections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NONINFECTIOUS VITRITIS AFTER INTRAVITREAL INJECTION OF ANTI-VEGF AGENTS: Variations in Rates and Presentation by Medication. https://app.cochat.ai/papers/10.1097/iae.0000000000000801
The paper
Williams, P. D., Chong, D., Fuller, T., & Callanan, D. (2016). NONINFECTIOUS VITRITIS AFTER INTRAVITREAL INJECTION OF ANTI-VEGF AGENTS: Variations in Rates and Presentation by Medication. Retina. https://doi.org/10.1097/iae.0000000000000801

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.